Apr 10 |
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
|
Mar 25 |
BioXcel launches $25M direct offering of stock and warrants
|
Mar 25 |
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
|
Mar 24 |
BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint
|
Mar 15 |
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
|
Mar 13 |
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript
|
Mar 13 |
Q4 2023 BioXcel Therapeutics Inc Earnings Call
|
Mar 12 |
BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript
|
Mar 12 |
BioXcel Therapeutics GAAP EPS of -$0.76 beats by $0.15, revenue of $0.38M misses by $0.36M
|
Mar 12 |
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
|